Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib tablet pharmacokinetics with itraconazole and QT assessment in advanced solid tumors
NL-OMON40540Phase 1Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of olaparib and itraconazole in Nonhematologic neoplasms (3 arms), sponsored by AstraZeneca. Primary endpoints: Maximum plasma olaparib concentration and Olaparib area under the concentration-time curve. Started Nov 2013; status: active, not recruiting.
02
Drugs
olaparibitraconazole
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON40540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40540.